ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug

seekingalpha06-22

Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2445720128?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg","is_english":true,"pubTime":"2024-06-22 20:27","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2445720128","market":"us","top_or_hot":-1,"title":"ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug","media":"seekingalpha","content":"<div>\n<p>Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy ...</p>\n\n<a href=\"https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-22 20:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy ...</p>\n\n<a href=\"https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound","article_id":"2445720128","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2445720128","pubTimestamp":1719059262,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Respiratory device makers ResMed , and Philips  traded lower on Friday after Eli Lilly  said an FDA decision on a potential label expansion for its weight loss therapy tirzepatide against obstructive sleep apnea  is expected later this year. The announcement hurt the shares of ResMed  and Philips , which dominate the market for CPAP  machines, an FDA-approved solution for OSA. Shares of Inspire Medical Systems , which offers a minimally invasive solution designed to treat the condition, also came under pressure. LLY’s announcement coincided with detailed results from its Phase 3 SURMOUNT-OSA program, in which tirzepatide, a dual GIP and GLP-1 receptor agonist, reached its main goals with or without PAP therapy. The Indiana-based drugmaker said it has already submitted regulatory filings with the FDA, seeking a label expansion for the once-weekly injectable for moderate-to-severe OSA and obesity. However, Axsome Therapeutics , which markets a therapeutic option for OSA in the form of it","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4581":"高盛持仓","BK4504":"桥水持仓","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","INSP":"Inspire Medical Systems","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","PHG":"飞利浦","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","RMD":"瑞思迈","AXSM":"Axsome Therapeutics, Inc.","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK4167":"医疗保健技术","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4588":"碎股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0122379950.USD":"贝莱德世界健康科学A2","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LLY":"礼来","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC"},"translate_title":"礼来寻求减肥药睡眠适应症，瑞思迈、飞利浦面临压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"PHG":1,"AXSM":1,"INSP":1,"LLY":1},"content_text":"Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy tirzepatide against obstructive sleep apnea (OSA) is expected later this year. The announcement hurt the shares of ResMed (RMD) and Philips (PHG), which dominate the market for CPAP (continuous positive airway pressure) machines, an FDA-approved solution for OSA. Shares of Inspire Medical Systems (INSP), which offers a minimally invasive solution designed to treat the condition, also came under pressure. LLY’s announcement coincided with detailed results from its Phase 3 SURMOUNT-OSA program, in which tirzepatide, a dual GIP and GLP-1 receptor agonist, reached its main goals with or without PAP therapy. The Indiana-based drugmaker said it has already submitted regulatory filings with the FDA, seeking a label expansion for the once-weekly injectable for moderate-to-severe OSA and obesity. However, Axsome Therapeutics (AXSM), which markets a therapeutic option for OSA in the form of its sleep disorder therapy Sunosi, traded higher. Similarly, in April, ResMed (RMD) and Philips (PHG) shares declined after LLY announced topline data from SURMOUNT-OSA, noting that two trials comprising the program reached main goals.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445720128"}